title: Phase II trial of cytarabine, cisplatin and vindesine for advanced non-small cell lung cancer.
abstract: Thirty-two patients with advanced non-small cell lung cancer (NSCLC) were entered in this study to evaluate the efficacy and toxicity of a chemotherapy schedule including cisplatin (C) 40 mg/m2 intravenously (i.v.) on days 1-3; vindesine (V) 3 mg/m2 i.v. on day 1, and cytarabine (ara-C) 15 mg/m2 subcutaneously every 12 hours on days 1-3 (total dose: 90 mg/m2). Cisplatin was administered simultaneously with one dose of ara-C. Cycles were repeated every 28 days. Five patients out of 28 (18%) fully evaluable for response presented partial remissions. No complete response was observed. Median survival was 8 months and median duration of response was 4 months. Hematologic toxicity was severe in 3 patients. There were no toxicity-related deaths. Other adverse reactions included nausea and vomiting, alopecia and peripheral neuropathy. We conclude that this chemotherapy combination is marginally effective against NSCLC showing in this group of patients a low number of responses of short duration without a significant impact on survival.
authors.affiliation: Instituto de Hematología y Oncología, Mar Del Plata, Argentina.
authors.forename: A
authors.initials: A
authors.lastname: Bianco
authors.forename: J E
authors.initials: JE
authors.lastname: Perez
authors.forename: M
authors.initials: M
authors.lastname: Machiavelli
authors.forename: B A
authors.initials: BA
authors.lastname: Leone
authors.forename: A
authors.initials: A
authors.lastname: Romero
authors.forename: M G
authors.initials: MG
authors.lastname: Rabinovich
authors.forename: C T
authors.initials: CT
authors.lastname: Vallejo
authors.forename: R
authors.initials: R
authors.lastname: Rodriguez
authors.forename: M A
authors.initials: MA
authors.lastname: Cuevas
authors.forename: L A
authors.initials: LA
authors.lastname: Alvarez
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D002945:Cisplatin; D014751:Vindesine